Equities research analysts predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will report sales of $410,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $100,000.00. Ultragenyx Pharmaceutical reported sales of $10,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 4,000%. The firm is expected to announce its next earnings report on Thursday, February 15th.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $410,000.00 for the current year, with estimates ranging from $190,000.00 to $2.36 million. For the next financial year, analysts expect that the business will post sales of $37.48 million per share, with estimates ranging from $2.60 million to $226.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.64) earnings per share.
Ultragenyx Pharmaceutical (NASDAQ RARE) opened at $44.68 on Friday. Ultragenyx Pharmaceutical has a 1-year low of $43.38 and a 1-year high of $91.35.
Institutional investors and hedge funds have recently modified their holdings of the business. Sei Investments Co. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $125,000. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical during the third quarter worth about $156,000. Tocqueville Asset Management L.P. grew its position in Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares during the period. Pacer Advisors Inc. grew its position in Ultragenyx Pharmaceutical by 12.0% during the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 365 shares during the period. Finally, Kazazian Asset Management LLC acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $213,000. Institutional investors own 94.13% of the company’s stock.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.